MAIA Biotechnology (NYSEAMERICAN:MAIA) Issues Earnings Results

MAIA Biotechnology (NYSEAMERICAN:MAIA) released its quarterly earnings results on Monday. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04, FiscalAI reports.

MAIA Biotechnology Stock Performance

MAIA Biotechnology stock traded down $0.01 during midday trading on Monday, reaching $1.32. The stock had a trading volume of 346,069 shares, compared to its average volume of 933,095. The stock has a market capitalization of $79.78 million, a PE ratio of -1.91 and a beta of 0.21. The stock’s 50-day simple moving average is $1.46 and its 200 day simple moving average is $1.52. MAIA Biotechnology has a twelve month low of $0.87 and a twelve month high of $3.19.

Hedge Funds Weigh In On MAIA Biotechnology

A number of hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC lifted its stake in shares of MAIA Biotechnology by 3.6% during the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after purchasing an additional 7,746 shares in the last quarter. Marshall Wace LLP acquired a new position in MAIA Biotechnology during the 2nd quarter worth approximately $29,000. Finally, Jane Street Group LLC purchased a new position in MAIA Biotechnology in the 2nd quarter worth approximately $52,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.